Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for patients with serious diseases, particularly cancer and other unmet medical needs. The company leverages its expertise in molecular biology and drug development to create targeted treatments that aim to improve patient outcomes. With a strong emphasis on research and clinical trials, Incyte strives to advance its pipeline of potential medications, which includes both its proprietary compounds and collaborations with other pharmaceutical partners. Through its commitment to scientific excellence and patient-centric approaches, Incyte aims to address significant healthcare challenges and enhance the quality of life for individuals suffering from complex conditions. Read More
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks ...
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of $24.69 billion.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $25.75 billion.
Incyte Corporation (Nasdaq: INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Company’s common stock and stock option awards to purchase an aggregate of 18,172 shares of the Company’s common stock to 24 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of August 3, 2026, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate.
Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA.
Excluding the $246 million one-time b
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on ...
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for. Incyte beat analy...
